Since in a type 2 diabetic patient hyperkalemia is more likely to occur with a steroidal mineralocorticoid receptor antagonist such as spironolactone or eplerenone, caution needs to be utilized through regular monitoring of serum potassium levels. This evidence concerns the gene NR3C2 and Hyperkalemia.